Keyword Analysis & Research: mdxhealth


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
mdxhealth1.230.81292719

Keyword Research: People who searched mdxhealth also searched

Keyword CPC PCC Volume Score
mdxhealth0.880.8360334
mdxhealth stock1.80.2220640
mdxhealth koers0.590.1922779
mdxhealth sa1.950.4160466
mdxhealth nasdaq1.690.5344872
mdxhealth nieuws0.140.7543697
mdxhealth yahoo nasdaq0.310.3700771
mdxhealth news1.920.1290293
mdxhealth forum1.030.361471
mdxhealth koers vandaag1.221636179
mdxhealth irvine ca0.230.5783782
mdxhealth aandeel0.29184661
mdxhealth koers nasdaq1.550.6259336

Search Results related to mdxhealth on Search Engine

  • Home - mdxhealth

    mdxhealth.com

    https://mdxhealth.com/

    WEBImproving the earlier detection of aggressive prostate cancer and urologic diseases with personalized molecular diagnostic solutions Learn More Improving the earlier detection of aggressive prostate cancer and urologic diseases with personalized molecular diagnostic solutions Learn More Mdxhealth Precision Prostate cancer pathway Delivering …

    DA: 81 PA: 89 MOZ Rank: 25

  • Select mdx for Patients - mdxhealth

    mdxhealth.com

    https://mdxhealth.com/select-mdx-for-patients/

    WEBPatients. If you have an elevated PSA level, it is important to understand your risk for aggressive, potentially lethal, prostate cancer. Overview · Downloads · Pay My Bill. Are You At-Risk for Aggressive Prostate Cancer? The Select mdx Test …

    DA: 18 PA: 24 MOZ Rank: 39

  • MDxHealth SA (MDXH) Stock Price, News, Quote & History

    yahoo.com

    https://finance.yahoo.com/quote/MDXH/

    WEBMDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally.

    DA: 23 PA: 58 MOZ Rank: 38

  • mdxhealth | LinkedIn

    linkedin.com

    https://www.linkedin.com/company/mdxhealth

    WEBmdxhealth | LinkedIn. Biotechnology Research. Irvine, CA 6,295 followers. Molecular Diagnostic Solutions for Prostate Cancer. View all 259 employees. About us. Mdxhealth is a multinational...

    DA: 78 PA: 28 MOZ Rank: 11

  • Mdxhealth Announces Fourth Quarter and Full-Year 2023 …

    yahoo.com

    https://finance.yahoo.com/news/mdxhealth-announces-fourth-quarter-full-210000297.html

    WEBMar 6, 2024 · Key Highlights: Completed transition to sole listing of its shares on NASDAQ. Secured Medicare coverage for the Company’s Select mdx test. Fourth quarter revenue of $19.4 million, an increase of...

    DA: 81 PA: 72 MOZ Rank: 88


  • Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer …

    yahoo.com

    https://finance.yahoo.com/news/mdxhealth-acquires-oncotype-dx-gps-200000669.html

    WEBAug 2, 2022 · mdxhealth. NEWS RELEASE – INSIDE AND REGULATED INFORMATION. August 2, 2022, 4:00PM EDT / 22:00 CET. Mdxhealth Acquires Oncotype DX® GPS Prostate Cancer Business. from Exact Sciences and Reports...

    DA: 36 PA: 22 MOZ Rank: 92

  • MDxHealth (MDXH) Earnings Date and Reports 2024 - MarketBeat

    marketbeat.com

    https://www.marketbeat.com/stocks/NASDAQ/MDXH/earnings/

    WEB1 day ago · MDXH Earnings Date and Information. MDxHealth last posted its quarterly earnings results on March 6th, 2024. The reported ($0.39) EPS for the quarter. The business earned $19.40 million during the quarter. MDxHealth has generated $0.00 earnings per share over the last year. Earnings for MDxHealth are expected to grow in …

    DA: 30 PA: 59 MOZ Rank: 74

  • Commercialized Blood-, Urinary- and Tissue-Based Biomarker …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765473/

    WEBDec 16, 2020 · 1. Introduction. Prostate cancer (PCa) is one of the most frequently diagnosed cancers in men. Estimates for 2018 predicted 1.28 million new diagnosed PCa cases, associated with over 358,000 deaths [].The serum prostate-specific antigen (sPSA) test is widely used in multiple clinical phases of disease; PCa detection, risk stratification …

    DA: 62 PA: 93 MOZ Rank: 57

  • A Rich Array of Prostate Cancer Molecular Biomarkers: …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6515282/

    WEBApr 12, 2019 · A rich array of prostate cancer diagnostic and prognostic tests has emerged for serum (4K, phi), urine (Progensa, T2-ERG, ExoDx, SelectMDx), and tumor tissue (ConfirmMDx, Prolaris, Oncoytype DX, Decipher). The development of these assays has created new opportunities for improving prostate cancer diagnosis, prognosis, and …

    DA: 52 PA: 11 MOZ Rank: 83

  • Modern biomarkers in prostate cancer diagnosis - PMC

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7587476/

    WEBAug 7, 2020 · The most common malignant neoplasm of the urinary tract is prostate cancer (PCa), which is a heterogeneous disease, ranging from very slowly developing and slightly benign to progressing, aggressive, metastatic and fatal, even when properly treated. Existing, imperfect diagnostic methods often lead to over-diagnosis and over-treatment …

    DA: 2 PA: 77 MOZ Rank: 83